Patents by Inventor Chunyan Yang
Chunyan Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092922Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.Type: ApplicationFiled: September 11, 2023Publication date: March 21, 2024Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen
-
Patent number: 10537629Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: March 19, 2018Date of Patent: January 21, 2020Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Publication number: 20180207257Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: ApplicationFiled: March 19, 2018Publication date: July 26, 2018Inventors: Jun ZHANG, Jin WANG, Chunyan YANG, Ying GU, Shaowei LI, Ningshao XIA
-
Patent number: 9943586Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: November 14, 2016Date of Patent: April 17, 2018Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Patent number: 9764028Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.Type: GrantFiled: August 26, 2016Date of Patent: September 19, 2017Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
-
Patent number: 9757450Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.Type: GrantFiled: August 26, 2016Date of Patent: September 12, 2017Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
-
Publication number: 20170065708Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: ApplicationFiled: November 14, 2016Publication date: March 9, 2017Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Publication number: 20170014506Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.Type: ApplicationFiled: August 26, 2016Publication date: January 19, 2017Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
-
Publication number: 20170015713Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.Type: ApplicationFiled: August 26, 2016Publication date: January 19, 2017Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
-
Patent number: 9533035Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: January 3, 2017Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Patent number: 9512185Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.Type: GrantFiled: June 1, 2012Date of Patent: December 6, 2016Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
-
Patent number: 9269852Abstract: A semiconductor light-emitting diode, including: an n-GaN layer, a quantum well layer, an electron blocking layer, and a p-GaN layer, which are sequentially stacked on a substrate. The electron blocking layer includes at least one first AlGaN layer and at least one second AlGaN layer. The first AlGaN layer and the second AlGaN layer are alternately stacked. The adjacent first and second AlGaN layers have different Al component.Type: GrantFiled: September 6, 2014Date of Patent: February 23, 2016Assignee: HC SEMITEK CORPORATIONInventors: Wenbing Li, Jiangbo Wang, Binzhong Dong, Chunyan Yang
-
Publication number: 20140374700Abstract: A semiconductor light-emitting diode, including: an n-GaN layer, a quantum well layer, an electron blocking layer, and a p-GaN layer, which are sequentially stacked on a substrate. The electron blocking layer includes at least one first AlGaN layer and at least one second AlGaN layer. The first AlGaN layer and the second AlGaN layer are alternately stacked. The adjacent first and second AlGaN layers have different Al component.Type: ApplicationFiled: September 6, 2014Publication date: December 25, 2014Inventors: Wenbing LI, Jiangbo WANG, Binzhong DONG, Chunyan YANG
-
Publication number: 20140134199Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.Type: ApplicationFiled: June 1, 2012Publication date: May 15, 2014Applicants: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITYInventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
-
Patent number: 8290374Abstract: A dispersion compensation method and a dispersion compensation device in an optical communication system are provided. The method mainly includes the following steps. A dispersion compensation value transmitted through a working path at a second wavelength is received through a non-working path at a first wavelength in an optical communication system. The non-working path at the first wavelength and the working path at the second wavelength use the same service channel. Dispersion in the non-working path at the first wavelength is compensated according to the dispersion compensation value. Therefore, no matter the working path is a main path or a backup path, the dispersion compensation value on the non-working path can be accurately regulated in time, such that the dispersion of the working path reaches an optimal status each time after the protection switching occurs to the service, thereby ensuring the fast switching of the service.Type: GrantFiled: December 23, 2009Date of Patent: October 16, 2012Assignee: Huawei Technologies Co., Ltd.Inventors: Junrui Li, Jing Nui, Chunyan Yang, Changbin Hu, Kai Liu
-
Publication number: 20100291141Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: ApplicationFiled: May 29, 2008Publication date: November 18, 2010Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
-
Publication number: 20100166435Abstract: A dispersion compensation method and a dispersion compensation device in an optical communication system are provided. The method mainly includes the following steps. A dispersion compensation value transmitted through a working path at a second wavelength is received through a non-working path at a first wavelength in an optical communication system. The non-working path at the first wavelength and the working path at the second wavelength use the same service channel. Dispersion in the non-working path at the first wavelength is compensated according to the dispersion compensation value. Therefore, no matter the working path is a main path or a backup path, the dispersion compensation value on the non-working path can be accurately regulated in time, such that the dispersion of the working path reaches an optimal status each time after the protection switching occurs to the service, thereby ensuring the fast switching of the service.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: HUAWEI TECHNOLOGIES CO., LTD.Inventors: Junrui Li, Jing Niu, Chunyan Yang, Changbin Hu, Kai Liu
-
Patent number: D829389Type: GrantFiled: March 23, 2017Date of Patent: September 25, 2018Inventors: Zhangli Lan, Jian Li, Yukun Yang, Chunyan Yang
-
Patent number: D1023845Type: GrantFiled: December 29, 2023Date of Patent: April 23, 2024Inventor: Chunyan Yang